Effect of Hydrocortisone on Death, Organ Support in Patients With Severe COVID-19

JAMA

EMBARGOED FOR RELEASE: 10 A.M. (ET), WEDNESDAY, SEPTEMBER 2, 2020

Media advisory: The full study and editorial are linked to this news release. A visual abstract is below. This study is being published to coincide with the release of guidelines from the World Health Organization regarding use of corticosteroids for treatment of critically ill COVID-19 patients.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17022?guestAccessKey=23fa39bc-68d3-4d4a-88ef-37c908849a05&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090220

 

What The Study Did: This randomized clinical trial of patients with severe COVID-19 was stopped early after results from another trial were released but this study investigated whether intravenous hydrocortisone (administered either as a seven-day fixed-dose course or restricted to when shock is clinically evident) improved 21-day organ support–free days.

Authors: Derek C. Angus, M.D., M.P.H., of the University of Pittsburgh, is the corresponding author.

 

Visual Abstract

(doi:10.1001/jama.2020.17022)

Editor’s Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.